Copy
Check out the new Companies-to-Follow List for 2023
CRISPR Medicine News |  15 March 2023
Base Editors | Off-target | Delivery | CAR-TTrials | Microbiome | Advertising | Webinars
Intellia Therapeutics Gets FDA Green Light to Initiate U.S. CRISPR Trial for Hereditary Angioedema


Intellia Therapeutics recently announced that the FDA has cleared an Investigational New Drug application for NTLA-2002, a single-dose in vivo CRISPR therapeutic candidate designed to cure hereditary angioedema. This allows the company to include the United States in the global Phase 2 portion of Intellia's ongoing Phase 1/2 trial of NTLA-2002.


Read the article here...
Selected Articles 
Cas12a chRDNA - A Novel Approach to Gene-Editing Therapy
Clinical Trial Roundup: Gene-Editing Therapies for Renal Cell Carcinoma
Novel CRISPR-Cas13d Therapy for Huntington’s Disease
Clinical Trial Update - Encouraging Safety and Efficacy Data From Phase 1 TALEN Trial in Multiple Myeloma
A Gene-Edited Cell Therapy for an Incurable Disease
Gene-Editing Clinical Trials: Highlights of 2022
Overview: Diseases That Gene Editors Potentially Could Cure
Events 2023

CRISPR - Genome Editing in Medicine and Agriculture

Date: April 16, 2023

Venue Site:
The David Lopatie Conference Centre, Weizmann Institute of Science, Israel

CAR T Cell Therapy and Advances in Cellular Engineering

Dates: June 6-7, 2023

Venue Site:
Oticon salen, Technical University of Denmark, 2800 Lyngby, Denmark

Advertise on CMN in 2023
Thank you for now - more great reads are on the way!
And if you have questions or suggestions, you can reach out to us directly at:
TheEditor@crisprmedicinenews.com
We love hearing from readers!

Happy Reading!

The CMN Team

LinkedIn
Twitter
Copyright © 2023 CRISPR Medicine News, All rights reserved.

Our mailing address is:
TheEditor@crisprmedicinenews.com

Access to CMN Newsletter archive using this link

Want to unsubscribe from these emails?
Unsubscribe from this list.